SH2scan Unlocks a New Era of SH2 Domain Selectivity Profiling

Understanding how small molecules interact with their protein targets — and importantly, their off-targets — is one of the biggest challenges in drug discovery. This is especially true for Src Homology 2 (SH2) domains, a family of 120 protein–protein interaction modules involved in key signaling pathways across inflammation and oncology. Yet despite their therapeutic relevance, efforts to design selective SH2-targeting ligands have been slowed by a lack of scalable systems for evaluating binding specificity. Traditional tools often provide partial coverage, limited throughput, or only phosphopeptide-based interactions — leaving major gaps in understanding synthetic ligand behavior.

A new publication from Eurofins Discovery introduces a solution: SH2scan^®, a first-of-its-kind, high-throughput competition binding assay platform that profiles synthetic ligands across >80% of canonical human SH2 domains. This work opens the door to clearer SAR decisions, earlier off-target identification, and new molecular probe discovery.

What is SH2scan?

SH2scan is a plate-based competition binding assay that uses DNA-tagged SH2 domain constructs and phosphopeptide-coated magnetic beads to quantitatively measure ligand binding. By monitoring displacement of the tagged protein via qPCR, the system generates accurate dissociation constants (K_Ds) and selectivity fingerprints for each ligand–domain interaction.

The platform includes:

• 95 SH2 domain-containing constructs (covering 97 domains total)
• >80% coverage of canonical SH2 domains
• 7 mutant STAT constructs
• Optimized assay conditions ensuring true thermodynamic K_D values

This enables SH2scan to map how compounds bind across the entire target class — something not previously possible at scale.

The Study: Profiling 9 Synthetic SH2-Targeting Ligands

To demonstrate platform capabilities, the team profiled nine ligands from the literature, including:

• SRC family SH2 domain binders (Ac-pYEEIE-NH₂, caffeic acid-pYEEIE)
• Selective ligands for GRB2, SOCS2, STAT3, STAT5B, STAT6
• A heterobifunctional degrader (SD-36)

Each compound underwent:

• Primary screening at 10 μM
• Dose-response validation
• K_D extraction using the Hill equation

This produced a comprehensive selectivity map across the SH2 domain family.

Key Findings

1. Selectivity varies dramatically across ligands
   • Caffeic acid-pYEEIE bound ~70% of constructs (71/102), with K_Ds as low as 0.53 nM.
   • Ac-pYEEIE-NH₂, despite being structurally similar, bound to only a handful of SH2 domains.

   A small structural change resulted in completely different selectivity.

2. SH2scan confirmed expected on-target engagement

   For example:

   • CGP78850: 3.4 nM KD for GRB2
   • STAT6-IN-1 and STAT6-IN-3: strong binding to STAT6 (0.68–8.6 nM)
3. Novel off-target interactions were identified. These included:
   • Strong binding of STAT6-IN-1 and STAT6-IN-3 to SOCS4 (10–13 nM)
   • MN551 engaging SOCS4 and CISH

   These insights can help teams anticipate potential liabilities earlier in discovery.

4. The assay platform is highly robust
   • False positive rate: 3.8%
   • False negative rate: 1.0%

   Both fall below typical screening thresholds.

5. SAR relationships become clearer with target-class–wide profiling

   The difference of one methyl group between STAT6-IN-1 and STAT6-IN-3 resulted in:

   • Higher potency (STAT6-IN-1)
   • But more off-target interactions

   SH2scan helps illuminate these trade-offs.

Why SH2scan Matters

For Drug Discovery

• Early detection of off-targets
• Better-informed SAR campaigns
• Reduced project risk

For Chemical Biology

• Discovery of new molecular probes
• Ability to interrogate under-characterized SH2 domains

For Therapeutic Innovation

• More selective, safer inhibitors
• Improved understanding of SH2-driven signaling

A New Chapter for SH2 Domain Research

SH2scan represents one of the most comprehensive solutions for profiling SH2 domain selectivity. By enabling broad, quantitative mapping of ligand interactions, SH2scan gives researchers the clarity they need to design more selective and effective molecules.

Read the full publication https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c02613